“Even as critics accused Moderna of overhyping the results released on May 18, a series of transactions were executed before its share price fizzled over the next week. The timing of those deals, former SEC officials said, appear to be ‘highly problematic‘ and should be investigated for potential illegal market manipulation.” And Gilead trades that made millions on COVID-19 drug news raise eyebrows. (While eyebrows are up, I’d love for someone to take a look at who benefited financially from the Hydroxychloroquine hype.)